Inloggad som:
BLU 667-2303
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
BLU 667-2303
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cance
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cance
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studysonia (2022-05-04)